These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16937104)

  • 21. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
    Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
    Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
    Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical studies with Erlotinib (Tarceva).
    Akita RW; Sliwkowski MX
    Semin Oncol; 2003 Jun; 30(3 Suppl 7):15-24. PubMed ID: 12840797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.
    Alami N; Page V; Yu Q; Jerome L; Paterson J; Shiry L; Leyland-Jones B
    Growth Horm IGF Res; 2008 Dec; 18(6):487-96. PubMed ID: 18502161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].
    Yanagisawa M; Ishikawa T; Ouchi KF; Tanaka Y
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):223-30. PubMed ID: 12610870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cao S; Rustum YM
    Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
    Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice.
    Lin P; An F; Xu X; Zhao L; Liu L; Liu N; Wang P; Liu J; Wang L; Li M
    Biochem Biophys Res Commun; 2015 May; 460(2):362-7. PubMed ID: 25791480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib (Tarceva): an update on the clinical trial program.
    Herbst RS
    Semin Oncol; 2003 Jun; 30(3 Suppl 7):34-46. PubMed ID: 12840799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
    Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
    J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
    Zhang D; Tari AM; Akar U; Arun BK; LaFortune TA; Nieves-Alicea R; Hortobagyi GN; Ueno NT
    Mol Cancer Ther; 2010 Nov; 9(11):3090-9. PubMed ID: 21045138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
    Mahller YY; Vaikunth SS; Currier MA; Miller SJ; Ripberger MC; Hsu YH; Mehrian-Shai R; Collins MH; Crombleholme TM; Ratner N; Cripe TP
    Mol Ther; 2007 Feb; 15(2):279-86. PubMed ID: 17235305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
    Gordon AN; Finkler N; Edwards RP; Garcia AA; Crozier M; Irwin DH; Barrett E
    Int J Gynecol Cancer; 2005; 15(5):785-92. PubMed ID: 16174225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.